Pazopanib for the treatment of soft-tissue sarcoma

被引：17

作者：

Heudel, Pierre ^{[1
]}

Cassier, Philippe ^{[1
]}

Derbel, Olfa ^{[1
]}

Dufresne, Armelle ^{[1
]}

Meeus, Pierre ^{[2
]}

Thiesse, Philippe ^{[3
]}

Ranchere-Vince, Dominique ^{[4
]}

Blay, Jean Yves ^{[1
]}

Ray-Coquard, Isabelle ^{[1
,5
]}

机构：

[1] Leon Berard Ctr, Med Oncol Dept, 28 Rue Laennec, F-69008 Lyon, France

[2] Leon Berard Ctr, Dept Surg Oncol, Lyon, France

[3] Leon Berard Ctr, Dept Radiol, Lyon, France

[4] Leon Berard Ctr, Dept Pathol, Lyon, France

[5] Lyon Univ, Sante Individu Soc, EAM 4128, Lyon, France

来源：

CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS | 2012年 / 4卷

关键词：

soft-tissue sarcoma; pazopanib; tyrosine kinase inhibitor;

D O I：

10.2147/CPAA.S33195

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pazopanib is a multikinase inhibitor which potently inhibits the activity of major receptor tyrosine kinases, including vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, platelet-derived growth factor receptor-a, platelet-derived growth factor receptor-a, and c-Kit. Approved by the Food and Drug Administration in 2009 in the United States for the treatment of metastatic renal cell carcinoma, pazopanib has been tested in advanced or metastatic soft-tissue sarcoma. Unlike other tyrosine kinase inhibitors, a statistically significant efficacy in phase II but also in randomized phase III studies has been shown. In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated. This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas.

引用

页码：65 / 70

页数：6

共 25 条

[1] Soft tissue sarcomas: are all soft tissue sarcomas treated with the same drugs? [J].

Blay, Jean-Yves ;

Cassier, Philippe A. ;

Ray-Coquard, Isabelle .

EUROPEAN JOURNAL OF CANCER, 2011, 47 :S385-S388

[2] Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma [J].

Bukowski, Ronald M. .

EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (05) :635-645

[3] Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Casali, P. G. ;

Blay, J. -Y. .

ANNALS OF ONCOLOGY, 2010, 21 :v198-v203

[4] Therapeutic pipeline for soft-tissue sarcoma [J].

Cassier, Philippe A. ;

Labidi-Galy, Sana Intidhar ;

Heudel, Pierre ;

Dutour, Aurelie ;

Meeus, Pierre ;

Chelghoum, Maria ;

Alberti, Laurent ;

Ray-Coquard, Isabelle ;

Blay, Jean-Yves .

EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (16) :2479-2491

[5] Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). [J].

Chawla, S. P. ;

Blay, J. ;

Ray-Coquard, I. L. ;

Le Cesne, A. ;

Staddon, A. P. ;

Milhem, M. M. ;

Penel, N. ;

Riedel, R. F. ;

Nguyen, B. Bui ;

Cranmer, L. D. ;

Reichardt, P. ;

Bompas, E. ;

Song, Y. ;

Lee, R. ;

Eid, J. E. ;

Loewy, J. ;

Haluska, F. G. ;

Dodion, P. F. ;

Demetri, G. D. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[6] Medical progress: Soft-tissue sarcomas in adults [J].

Clark, MA ;

Fisher, C ;

Judson, I ;

Thomas, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (07) :701-711

[7] Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group [J].

du Bois, A. ;

Vergote, I. ;

Wimberger, P. ;

Ray-Coquard, I. ;

Harter, P. ;

Curtis, L. B. ;

Mitrica, I. .

BRITISH JOURNAL OF CANCER, 2012, 106 (04) :629-632

[8] Markers of angiogenesis and clinical features in patients with sarcoma [J].

DuBois, Steven ;

Demetri, George .

CANCER, 2007, 109 (05) :813-819

[9] Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas [J].

George, Suzanne ;

Merriam, Priscilla ;

Maki, Robert G. ;

Van den Abbeele, Annick D. ;

Yap, Jeffrey T. ;

Akhurst, Timothy ;

Harmon, David C. ;

Bhuchar, Gauri ;

O'Mara, Margaret M. ;

D'Adamo, David R. ;

Morgan, Jeffrey ;

Schwartz, Gary K. ;

Wagner, Andrew J. ;

Butrynski, James E. ;

Demetri, George D. ;

Keohan, Mary L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3154-3160

[10] Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor [J].

Harris, Philip A. ;

Boloor, Amogh ;

Cheung, Mui ;

Kumar, Rakesh ;

Crosby, Renae M. ;

Davis-Ward, Ronda G. ;

Epperly, Andrea H. ;

Hinkle, Kevin W. ;

Hunter, Robert N., III ;

Johnson, Jennifer H. ;

Knick, Victoria B. ;

Laudeman, Christopher P. ;

Luttrell, Deirdre K. ;

Mook, Robert A. ;

Nolte, Robert T. ;

Rudolph, Sharon K. ;

Szewczyk, Jerzy R. ;

Truesdale, Anne T. ;

Veal, James M. ;

Wang, Liping ;

Stafford, Jeffrey A. .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (15) :4632-4640

← 1 2 3 →